CTMX Stock — CytomX Therapeutics Inc.: Cash, EV, Pipeline

Share price

$2.76

Market cap

$601.4M

Cash

$330.3M

Enterprise value

$271.1M

Balance sheet

Cash	$330.3M
Debt	$0.0M
Net cash	$330.3M
Enterprise value	$271.1M
Basic shares	218.9M shares
Fully diluted shares	254.1M shares
Fully diluted market cap	$701.4M
Cash per share	$1.51

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading CTMX daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 11 - Feb 22	CX-2051	Phase 1	Solid Tumor, Adult	—
Apr 10 - May 22	CX-801	Phase 1	Solid Tumor, Adult	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Varsetatug masetecan

Phase 1 · Active Modality: conditionally activated antibody-drug conjugate (PROBODY)

Aliases Varseta-M

Target EpCAM

Partnerships AbbVie/ImmunoGen (topoisomerase-1 inhibitor payload license)

Indications

metastatic colorectal cancer (Phase 1)
gastric/GEJ cancer (Phase 1)
pancreatic ductal adenocarcinoma (Phase 1)
biliary tract cancer (Phase 1)

Catalysts

— Q4 2026
— Q3 2026

Status note Most advanced program; Phase 1 in EpCAM-expressing solid tumors since April 2024; no discontinuation disclosed.

CX-801

Phase 1 · Active Modality: masked conditionally activated cytokine (PROBODY)

Target interferon alpha-2b

Partnerships Merck (KEYTRUDA supply collaboration)

Indications

late-line melanoma (with and without KEYTRUDA) (Phase 1)

Catalysts

— H1 2027

Status note Phase 1 dose escalation since Q3 2024; no discontinuation disclosed.

CX-908

Preclinical · Active Modality: PROBODY T cell engager

Target CDH3; CD3

Partnerships Amgen (originated program)

Indications

not disclosed (Preclinical)

Status note Preclinical TCE program selected from Amgen pipeline; no discontinuation disclosed.

CX-904

Phase 1 · Terminated Modality: conditionally activated T-cell engager

Target EGFR

Partnerships Amgen (collaboration terminated)

Indications

not disclosed (Phase 1)

Status note Jointly discontinued by CytomX and Amgen in March 2025 after Phase 1; Amgen terminated rights effective Q2 2025.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	CX-2051
Lead indication	Solid Tumor, Adult
Lead phase	Phase 1
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06265688	Phase 1	Recruiting	Sponsor	CytomX Therapeutics	—	Solid Tumor, Adult	—
NCT06462794	Phase 1	Recruiting	Sponsor	CytomX Therapeutics	MRK	Solid Tumor, Adult	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for CytomX Therapeutics on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Baker Bros. Advisors	4,975,826	no change	0.09%	2026-08-14
ADAR1 Capital Management	3,365,118	-45,072	0.59%	2026-08-14
Sphera Biotech	879,000	+659,000	0.47%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

CTMX — CytomX Therapeutics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders